Departure of Directors or Certain

On July 6, 2016, with the recommendation of the Compensation Committee of the Board of Directors (the

Board

) of Biocept, Inc. (the

Company

), the Board approved the following retention awards consisting of restricted stock units (

RSUs

):

Name

RSUs

Michael W. Nall,

President and Chief Executive Officer

75,000

Lyle J. Arnold, Ph.D.,

Senior Vice-President of Research & Development

50,000

Veena Singh, M.D.,

Senior Vice President and Senior Medical Director

50,000

Each of these RSUs were granted pursuant to the Companys Amended and Restated 2013 Equity Incentive Plan. Subject to eac h executive officers continuous service, 100% of each RSU will vest on the 12-month anniversary of the date of grant.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOCEPT, INC.

Dated: July 7, 2016

By:

/s/ Michael W. Nall

Name:

Michael W. Nall

Title:

Chief Executive Officer

makes a similar move, sign up!

Other recent filings from the company include the following:

Biocept director just picked up 5,667 shares - March 29, 2017
Biocept just filed a prospectus, suggesting it plans to soon issue some securities - March 29, 2017
Biocept Just Filed Its Annual Report: 12. Net Loss per Co... - March 28, 2017
Shareholder Director - March 23, 2017
CFO of Biocept was just granted 16,383 options - March 22, 2017

Auto Refresh

Feedback